References
- Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–7.
- Ball J, Carrington MJ, McMurray JJV, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807–1824.
- Rosner GF, Reiffel JA, Hickey K. The concept of “burden” in atrial fibrillation. J Atr Fibrillation. 2012;4(5):400.
- Kirchhof, P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
- Lip GYH, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46(1):143–150.
- Massaro A, Giugliano RP, Norrving B, et al. Overcoming global challenges in stroke prophylaxis in atrial fibrillation: the role of non-vitamin K antagonist oral anticoagulants. Int J Stroke. 2016;11(9):950–967.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
- Granger, CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
- Patel, MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
- Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the USA: the REVISIT-US study. Curr Med Res Opin. 2016;32(12):2047–2053.
- Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation–the RELIEF study. Int J Cardiol. 2016;203:882–884.
- Coleman CI, Haas S, Turpie AGG, et al. Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol. 2016;39(10):565–569.
- Coleman CI, Tangirala M, Evers T, et al. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the USA. PLoS One. 2016;11(6):e0157769.
- Ruff, CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
- Mekaj Y, Mekaj A, Duci S, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977.
- Walsh, C, Murphy A, Kirby A, et al. Retrospective costing of warfarin. Ir Med J. 2014;107(5):133–135.
- de Pouvourville G. Comment améliorer le suivi des AVK et pour quel coût? [How can we improve the follow-up of VKA and for which cost?]. Arch Card Dis. 2016;8(2):169–173. French.
- Le Heuzey Jym, E., Lepillier, A., Fiorina, L., et al. La fibrillation atriale : données démographiques. Mise au point Rythmologie Realites-cardiologiques 2010.Available fromhttp://www.realites-cardiologiques.com/wp-content/uploads/2010/03/10.pdf
- L’Assurance Maladie en Ligne. Tarifs conventionnels [Conventional rates]. Available from: https://www.ameli.fr/medecin/exercice-liberal/facturation-remuneration/tarifs. French.
- Detournay B. Coût direct des AVK en France [Direct costs of VKAs in France]. Arch Card Dis. 2016;8(2):174–179. French.
- Haute Autorité de Santé. Choix méthodologiques pour l’évaluation économique à la HAS [Methodological choices for economic evaluation at HAS]. 2011. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf. French.
- Institut national de la statistique et des études économiques. Le découpage en unités urbaines de 2010. http://www.insee.fr/fr/themes/document.asp?reg_id=0&ref_id=ip1364%C2